RT Journal Article
SR Electronic
T1 Use of portable air cleaners to reduce aerosol transmission on a hospital COVID-19 ward
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.29.21254590
DO 10.1101/2021.03.29.21254590
A1 Buising, KL
A1 Schofield, R
A1 Irving, L
A1 Keywood, M
A1 Stevens, A
A1 Keogh, N
A1 Skidmore, G
A1 Wadlow, I
A1 Kevin, K
A1 Rismanchi, B
A1 Wheeler, AJ
A1 Humphries, RS
A1 Kainer, M
A1 McGain, F
A1 Monty, J
A1 Marshall, C
YR 2021
UL http://medrxiv.org/content/early/2021/03/31/2021.03.29.21254590.abstract
AB Objective To study the airflow, transmission and clearance of aerosols in the clinical spaces of a hospital ward that had been used to care for patients with COVID-19, and to examine the impact of portable air cleaners on aerosol clearance.Design Observational studySetting A single ward of a tertiary public hospital in Melbourne AustraliaIntervention Glycerine-based aerosol was used as a surrogate for respiratory aerosols. The transmission of aerosols from a single patient room into corridors and a nurses’ station in the ward was measured. The rate of clearance of aerosols was measured over time from the patient room, nurses’ station and ward corridors with and without air cleaners (also called portable HEPA filters).Results Aerosols rapidly travelled from the patient room into other parts of the ward. Air cleaners were effective in increasing the clearance of aerosols from the air in clinical spaces and reducing their spread to other areas. With two small domestic air cleaners in a single patient room of a hospital ward, 99% of aerosols could be cleared within 5.5 minutes.Conclusion Air cleaners may be useful in clinical spaces to help reduce the risk of healthcare acquired acquisition of respiratory viruses that are transmitted via aerosols. They are easy to deploy and are likely to be cost effective in a variety of healthcare settingsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by the Royal Melbourne HospitalAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Royal Melbourne Hospital human research ethics committee reviewed the manuscript and determined that it was exempt from requiring ethics approvalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are held by the researchers at the University of Melbourne